supplement applicant's response of September 10, 1999, and is made pursuant to agreements reached in the interview of October 5, 1999, discussed below. Reconsideration and allowance are hereby respectfully requested.

The interview, graciously granted, between Examiner Goldberg and the undersigned, the inventor Dr. Michael Tovey and the licensee's representative Sylvia Miller on October 5, 1999, is hereby gratefully acknowledged. At this interview, the rejections were discussed and amendments to the claims were proposed which should place the present application into condition for allowance. The issues discussed at the interview will be discussed below.

As to the method claims, the arguments submitted in applicant's amendment of September 10, 1999, were discussed, emphasizing that Sato does not treat tumors. The examiner indicated that he would be inclined to withdraw this art rejection in view of these arguments. However, the examiner stated that he believed that the language "amount in excess of a dose of the same interferon which induces a pathological response when parenterally administered" is indefinite and the examiner requested that claim 6 be amended to insert a minimum dosage. Accordingly, applicant agreed to insert the subject matter of claim 21 into claim 6 in order to obviate this issue and expedite allowance.

As to the composition claims, the examiner stated that high dose interferon for oral or nasal administration was known and therefore the compositions could not be allowed as the intended use was not a limitation in the composition claims. After some discussion of this issue, applicant suggested that the composition claims specify that the composition is in the form of

b

a lozenge or buccal tablet as such a composition form is not suggested by the prior art. The examiner indicated that such an amendment would be favorably considered.

Accordingly, composition claims 17-20 have now been deleted in favor of new claims 35-38. New claim 34 has now been added to insert a dependent claim specifying that the administration via oromucosal contact comprises bringing said interferon into contact with the mucosa lining the mouth and/or throat of the mammal being treated as is supported in the present specification, for example, at page 17, lines 16-22.

Accordingly, it is submitted that all of the claims now present in the case clearly define over the references of record and fully comply with 35 USC 112. Consideration of the present amendment and response in conjunction with applicant's amendment of September 10, 1999, and passage of the present application to issue is hereby earnestly solicited.

Please take note that a revocation and new power of attorney is being filed on even date herewith.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.

Attorneys for Applicant(s),

By: _____
ROGER L. BROWDY
Registration No. 25,618

RLB:al
419 Seventh Street, N.W.
Washington, D.C. 20004
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
roger\tovey1.sup

As of November 22, 1999, the address of Browdy and Neimark PLLC will be:
624 9th Street, NW, Suite 300
Washington, D.C. 20001

b